June 18th 2025
Tafasitamab-cxix gains FDA approval for relapsed follicular lymphoma, showcasing significant progression-free survival benefits in combination therapy.
January 17th 2025
December 10th 2024
Brentuximab Vedotin/Nivolumab Appears Well-Tolerated in Early-Stage cHL
June 13th 2023In part C of the phase 2 SGN35-027 trial evaluating brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine in patients with classical Hodgkin lymphoma, fewer than half of patients developed primarily low-grade peripheral neuropathy, and no cases of febrile neutropenia were observed.
Read More
FDA Grants SGX301 a Type A Meeting for the Treatment of CTCL
May 15th 2023The FLASH study and compatibility study of SGX301 led to promising safety and efficacy responses for the treatment of cutaneous T-cell lymphoma. Now, the FDA has granted a type A meeting to discuss the design of a second trial of SGX301.
Read More
Researchers Explore Novel Treatment Strategies CNS Lymphoma
March 30th 2023In an interview with Targeted Oncology, Craig Sauter, MD, discusses available treatments for patients with central nervous system lymphoma and research that will provide more developments moving forward in this space.
Read More
FDA’s ODAC Votes for Polatuzumab Plus R-CHP for Previously Untreated DLBCL
March 9th 2023In a vote of 11 to 2, the FDA's Oncologic Drugs Advisory Committee voted for the benefit/risk profile of polatuzumab vedotin in combination with R-CHP, based on findings from the confirmatory POLARIX trial.
Read More
New Solutions Continue to Show Up in the Lymphoma Treatment Landscape
March 9th 2023In an interview with Targeted Oncology, Matthew Matasar, MD, breaks down what he sees as some of the most exciting data in the field of treatment for patients with lymphoma and what the future may hold for this patient population.
Read More